Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.46 |
| ▸ | NOS2 | P35228 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11471109 | 0.71 | SLC6A2 (0.56) | NOS3NOS2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8551454 | 0.67 | — | — | |
| SCHEMBL1515117 | 0.67 | NOS3 (0.41) | NOS3NOS2MAPTCYP19A1NOS1 | |
| SCHEMBL8630301 | 0.66 | NOS3 (0.39) | NOS3NOS2TSHRMAPTCYP19A1 | |
| SCHEMBL5542044 | 0.66 | NOS3 (0.39) | NOS3NOS2TSHRMAPTSMN1; SMN2 | |
| SCHEMBL10388003 | 0.66 | NOS3 (0.39) | NOS3NOS2TSHRMAPTCYP19A1 | |
| SCHEMBL8935522 | 0.66 | CYP2D6 (0.40) | NOS3NOS2BCHEMAPTKDM4E | |
| SCHEMBL4370064 | 0.66 | NPC1 (0.40) | NOS2MAPTSMN1; SMN2KDM4E | |
| SCHEMBL14012390 | 0.65 | ALDH1A1 (0.42) | NOS3NOS2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7610196 | 0.65 | SLC6A2 (0.36) | NOS3NOS2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-25 | — | — | US | claimed |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | claimed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | claimed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AZI2, ADRA2A, ADRA2C | NOS3 1251/4885NOS2 473/4885BCHE 1854/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | NOS3 1378/4885NOS2 708/4885BCHE 2504/4885 |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | NOS3 476/4885NOS2 150/4885BCHE 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.